Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience

He-Jiun Jiang,1 Yen-Hsiang Chang,2 Yen-Hao Chen,3 Che-Wei Wu,4 Pei-Wen Wang,5 Pi-Jung Hsiao6 1Division of Endocrinology and Metabolism, Department of Internal Medicine, E-DA DaChang Hospital, Kaohsiung, Taiwan; 2Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwa...

Full description

Bibliographic Details
Main Authors: Jiang HJ, Chang YH, Chen YH, Wu CW, Wang PW, Hsiao PJ
Format: Article
Language:English
Published: Dove Medical Press 2021-09-01
Series:Cancer Management and Research
Subjects:
lenvatinib
radioiodine-refractory differentiated thyroid carcinoma (rrdtc)
disease control rate (dcr)
progression-free survival (pfs)
overall survival (os)
Online Access:https://www.dovepress.com/low-dose-of-lenvatinib-treatment-for-patients-of-radioiodine-refractor-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/low-dose-of-lenvatinib-treatment-for-patients-of-radioiodine-refractor-peer-reviewed-fulltext-article-CMAR

Similar Items